HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Travere Therapeutics Intelligence Report

Intelligence report

Intelligence Report · ~12 min read

Travere Therapeutics Intelligence Report

Generated from 2 signals · 2 evidence sources

Type

Company Intelligence Report

Generated

Aug 5, 2026

Confidence

Moderate Confidence · 74%

Evidence

12 items

Sources

9

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

Travere Therapeutics maintains an active intelligence profile across Nephrology, Drug, SGLT2 Inhibitor. 2 signals are linked with 0 investigate-priority items requiring leadership attention. Competitive pressure is low with high portfolio impact. Evidence coverage stands at 74% across 2 tracked sources. Highest-priority development: CDER Nitrosamine Impurity Acceptable Intake Limits. Regulatory precedent. Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Travere Therapeutics; the same agency is already in play for this signal, so precedent weight is higher.

Key Developments

Material intelligence events ranked by strategic relevance.

  1. regulatory

    CDER Nitrosamine Impurity Acceptable Intake Limits

    Regulatory precedent may inform portfolio positioning

    View detail
  2. regulatory

    FDA Accepts First In Silico Drug Development Tool Under ISTAND Program to Help Predict Drug-Induced Liver Injury

    Regulatory precedent may inform portfolio positioning

    View detail
  3. regulatory

    FDA AP — FILSPARI (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  4. regulatory

    GDUFA III Controlled Correspondence Enhancements

    Regulatory precedent may inform portfolio positioning

    View detail
  5. regulatory

    GDUFA III Enhancements to the Pre-ANDA Program

    Regulatory precedent may inform portfolio positioning

    View detail
  6. regulatory

    Over-The-Counter Monograph Drug User Fee Program (OMUFA)

    Regulatory precedent may inform portfolio positioning

    View detail
  7. regulatory

    Generic Drugs: Questions & Answers

    Regulatory precedent may inform portfolio positioning

    View detail
  8. regulatory

    FDA AP — FILSPARI (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  9. regulatory

    FDA AP — FILSPARI (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  10. regulatory

    FDA Drug Competition Action Plan | Improving the efficiency of the generic drug development, review, and approval process

    Regulatory precedent may inform portfolio positioning

    View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Opportunity score 47 with buyer quality 8 (Mid-Market). Competitive pressure: Low. Portfolio impact: High.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

  • CDER Nitrosamine Impurity Acceptable Intake Limits

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA Accepts First In Silico Drug Development Tool Under ISTAND Program to Help Predict Drug-Induced Liver Injury

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — FILSPARI (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • GDUFA III Controlled Correspondence Enhancements

    High Confidence · 95%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • GDUFA III Enhancements to the Pre-ANDA Program

    High Confidence · 95%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Over-The-Counter Monograph Drug User Fee Program (OMUFA)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Generic Drugs: Questions & Answers

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — FILSPARI (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — FILSPARI (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA Drug Competition Action Plan | Improving the efficiency of the generic drug development, review, and approval process

    Moderate Confidence · 84%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

  • FDA Accepts Supplemental NDA for Travere's Filspari (Sparsentan)

    Nephrology · Drug

  • FDA Accepts Supplement for FILSPARI (SPARSENTAN) by TRAVERE

    Nephrology · SGLT2 Inhibitor

PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.